Abstract
Double-blind controlled cholera-vaccine trials were carried out in rural East Pakistan in 1963 and 1964. Pretrial studies indicated that a whole-cell cholera vaccine of high mouse protective potency, at a dose of 0.5 ml, produced an antibody response and reaction pattern consistent with use in such trials. A purified Ogawa antigen, given at a dose of 100 μg, elicited no adverse reactions and evoked both agglutinating and vibriocidal antibodies against both Inaba and Ogawa test suspensions.
In the field, adverse reactions to the cholera vaccines occurred primarily among adults and were observed with both the whole-cell preparation and the purified Ogawa antigen. At the dose used in the field trials (0.4 ml), the reactions elicited by the whole-cell vaccine were acceptable to the population and no more marked than those following the locally prepared typhoid-paratyphoid vaccine. Delayed reactions to the whole-cell cholera vaccine were observed beginning 4 to 7 days after the vaccine was administered; the bulk of them (60%) did not interfere with work at any time; all resolved promptly; and none developed fluctuation or was associated with abscess formation.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Benenson A. S., Mosley W. H., Fahimuddin M., Oseasohn R. O. Cholera vaccine field trials in east Pakistan. 2. Effectiveness in the field. Bull World Health Organ. 1968;38(3):359–372. [PMC free article] [PubMed] [Google Scholar]
- Benenson A. S., Saad A., Mosley W. H. Serological studies in cholera. 2. The vibriocidal antibody response of cholera patients determined by a microtechnique. Bull World Health Organ. 1968;38(2):277–285. [PMC free article] [PubMed] [Google Scholar]
- Benenson A. S., Saad A., Paul M. Serological studies in cholera. I. Vibrio agglutinin response of cholera patients determined by a microtechnique. Bull World Health Organ. 1968;38(2):267–276. [PMC free article] [PubMed] [Google Scholar]
- Das Gupta A., Sinha R., Shrivastava D. L., De S. P., Taneja B. L., Rao M. S., Abou-Gareeb A. H. Controlled field trial of the effectiveness of cholera and cholera El Tor vaccines in Calcutta. Bull World Health Organ. 1967;37(3):371–385. [PMC free article] [PubMed] [Google Scholar]
- FEELEY J. C., PITTMAN M. LABORATORY ASSAYS OF CHOLERA VACCINE USED IN FIELD TRIAL IN EAST PAKISTAN, 1963. Lancet. 1965 Feb 27;1(7383):449–450. doi: 10.1016/s0140-6736(65)91585-0. [DOI] [PubMed] [Google Scholar]
- Felix A., Rainsford S. G., Stokes E. J. Antibody Response and Systemic Reactions after Inoculation of a New Type of T.A.B.C. Vaccine. Br Med J. 1941 Mar 22;1(4185):435–440. doi: 10.1136/bmj.1.4185.435. [DOI] [PMC free article] [PubMed] [Google Scholar]
- GOODNER K., SMITH H. L., Jr, STEMPEN H. Serologic diagnosis of cholera. J Albert Einstein Med Cent (Phila) 1960 Apr;8:143–147. [PubMed] [Google Scholar]
- OSEASOHN R. O., BENENSON A. S., FAHIMUDDIN M. FIELD TRIAL OF CHOLERA VACCINE IN RURAL EAST PAKISTAN. FIRST YEAR OF OBSERVATION. Lancet. 1965 Feb 27;1(7383):450–452. doi: 10.1016/s0140-6736(65)91586-2. [DOI] [PubMed] [Google Scholar]
- Watanabe Y., Verwey W. F. Protective antigens from El Tor vibrios. 1. The preparation and properties of a purified protective antigen from an El Tor vibrio (Ogawa subtype). Bull World Health Organ. 1965;32(6):809–821. [PMC free article] [PubMed] [Google Scholar]